Foghorn Therapeutics
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Employees
- 116
- Market Cap
- $439.8M
- Introduction
Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulator...
FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Foghorn Therapeutics Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT04965753
- Locations
- ๐บ๐ธ
Massachusetts General Hospital, Boston, Massachusetts, United States
๐บ๐ธUniversity of Miami Health System, Miami, Florida, United States
๐บ๐ธCity of Hope, Duarte, California, United States
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-05-18
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Foghorn Therapeutics Inc.
- Target Recruit Count
- 144
- Registration Number
- NCT04891757
- Locations
- ๐บ๐ธ
Dana Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธMD Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธCity of Hope National Medical Center, Duarte, California, United States
FHD-286 in Subjects With Metastatic Uveal Melanoma
- First Posted Date
- 2021-05-10
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Foghorn Therapeutics Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT04879017
- Locations
- ๐บ๐ธ
Dana Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธSidney Kimmel Cancer Center - Jefferson Health, Philadelphia, Pennsylvania, United States
๐บ๐ธUniversity of Miami Health System, Sylvester Comprehensive Cancer Center, Miami, Florida, United States